Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 30253078)

  • 1. Targeting immunotherapy for bladder cancer using anti-CD3× B7-H3 bispecific antibody.
    Ma W; Ma J; Ma P; Lei T; Zhao M; Zhang M
    Cancer Med; 2018 Oct; 7(10):5167-5177. PubMed ID: 30253078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2 as a promising target for cytotoxicity T cells in human melanoma therapy.
    Ma J; Han H; Liu D; Li W; Feng H; Xue X; Wu X; Niu G; Zhang G; Zhao Y; Liu C; Tao H; Gao B
    PLoS One; 2013; 8(8):e73261. PubMed ID: 24015299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ipilimumab augments antitumor activity of bispecific antibody-armed T cells.
    Yano H; Thakur A; Tomaszewski EN; Choi M; Deol A; Lum LG
    J Transl Med; 2014 Jul; 12():191. PubMed ID: 25008236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fully human anti-B7-H3 recombinant antibodies inhibited tumor growth by increasing T cell infiltration.
    Li L; Nian S; Liu Q; Zhang B; Jimu W; Li C; Huang Z; Hu Q; Huang Y; Yuan Q
    Int Immunopharmacol; 2024 May; 132():111926. PubMed ID: 38552297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The bispecific B7H3xCD3 antibody CC-3 induces T cell immunity against bone and soft tissue sarcomas.
    Holzmayer SJ; Liebel K; Hagelstein I; Salih HR; Märklin M
    Front Immunol; 2024; 15():1391954. PubMed ID: 38765008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switchable CAR T cell strategy against osteosarcoma.
    Hidalgo L; Somovilla-Crespo B; Garcia-Rodriguez P; Morales-Molina A; Rodriguez-Milla MA; Garcia-Castro J
    Cancer Immunol Immunother; 2023 Aug; 72(8):2623-2633. PubMed ID: 37062034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting osteosarcoma with canine B7-H3 CAR T cells and impact of CXCR2 Co-expression on functional activity.
    Cao JW; Lake J; Impastato R; Chow L; Perez L; Chubb L; Kurihara J; Verneris MR; Dow S
    Cancer Immunol Immunother; 2024 Mar; 73(5):77. PubMed ID: 38554158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MEK Inhibitor Augments Antitumor Activity of B7-H3-Redirected Bispecific Antibody.
    Li H; Huang C; Zhang Z; Feng Y; Wang Z; Tang X; Zhong K; Hu Y; Guo G; Zhou L; Guo W; Xu J; Yang H; Tong A
    Front Oncol; 2020; 10():1527. PubMed ID: 32984002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B7-H3 confers resistance to Vγ9Vδ2 T cell-mediated cytotoxicity in human colon cancer cells via the STAT3/ULBP2 axis.
    Lu H; Ma Y; Wang M; Shen J; Wu H; Li J; Gao N; Gu Y; Zhang X; Zhang G; Shi T; Chen W
    Cancer Immunol Immunother; 2021 May; 70(5):1213-1226. PubMed ID: 33119798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma.
    Brignole C; Calarco E; Bensa V; Giusto E; Perri P; Ciampi E; Corrias MV; Astigiano S; Cilli M; Loo D; Bonvini E; Pastorino F; Ponzoni M
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37775116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific antibody targeting both B7-H3 and PD-L1 exhibits superior antitumor activities.
    Li HY; Chen YL; Deng XN; Li HH; Tan J; Liu GJ; Zheng YJ; Pei M; Peng KT; Yue LL; Chen XJ; Liu Y; Zhao YS; Wang CH
    Acta Pharmacol Sin; 2023 Nov; 44(11):2322-2330. PubMed ID: 37328649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting both GD2 and B7-H3 using bispecific antibody improves tumor selectivity for GD2-positive tumors.
    Rosenkrans ZT; Erbe AK; Clemons NB; Feils AS; Medina-Guevara Y; Jeffery JJ; Barnhart TE; Engle JW; Sondel PM; Hernandez R
    bioRxiv; 2024 May; ():. PubMed ID: 38853889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific T cell engager-armed T cells targeting integrin ανβ6 exhibit enhanced T cell redirection and antitumor activity in cholangiocarcinoma.
    Suwanchiwasiri K; Phanthaphol N; Somboonpatarakun C; Yuti P; Sujjitjoon J; Luangwattananun P; Maher J; Yenchitsomanus PT; Junking M
    Biomed Pharmacother; 2024 Jun; 175():116718. PubMed ID: 38744221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B7-H3 targeted antibody-based immunotherapy of malignant diseases.
    Michelakos T; Kontos F; Barakat O; Maggs L; Schwab JH; Ferrone CR; Ferrone S
    Expert Opin Biol Ther; 2021 May; 21(5):587-602. PubMed ID: 33301369
    [No Abstract]   [Full Text] [Related]  

  • 15. Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma.
    Podojil JR; Glaser AP; Baker D; Courtois ET; Fantini D; Yu Y; Eaton V; Sivajothi S; Chiang M; Das A; McLaughlin KA; Robson P; Miller SD; Meeks JJ
    Oncoimmunology; 2020; 9(1):1744897. PubMed ID: 32363111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro synthesis of primary specific anti-breast cancer antibodies by normal human peripheral blood mononuclear cells.
    Thakur A; Norkina O; Lum LG
    Cancer Immunol Immunother; 2011 Dec; 60(12):1707-20. PubMed ID: 21713642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Fc-modified monoclonal antibody as novel treatment option for pancreatic cancer.
    Lutz MS; Wang K; Jung G; Salih HR; Hagelstein I
    Front Immunol; 2024; 15():1343929. PubMed ID: 38322253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B7-H3 at the crossroads between tumor plasticity and colorectal cancer progression: a potential target for therapeutic intervention.
    Varghese E; Samuel SM; Brockmueller A; Shakibaei M; Kubatka P; Büsselberg D
    Cancer Metastasis Rev; 2024 Mar; 43(1):115-133. PubMed ID: 37768439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: a pilot clinical trial.
    Riechelmann H; Wiesneth M; Schauwecker P; Reinhardt P; Gronau S; Schmitt A; Schroen C; Atz J; Schmitt M
    Cancer Immunol Immunother; 2007 Sep; 56(9):1397-406. PubMed ID: 17273869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B7-H3 is associated with the armored-cold phenotype and predicts poor immune checkpoint blockade response in melanoma.
    Shen B; Mei J; Xu R; Cai Y; Wan M; Zhou J; Ding J; Zhu Y
    Pathol Res Pract; 2024 Apr; 256():155267. PubMed ID: 38520953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.